Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease largely affecting women over 50 years of age
Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version, a biobetter, of Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease largely affecting women over 50 years of age.
“The collective strengths of Paras Biopharmaceuticals’ and Novozymes’ technical expertise will bring solutions and treatment options to help osteoporosis patients,” says Dr Hans Söderlund, Director, Global Strategic Alliance at Paras Biopharmaceuticals Finland Oy. “Novozymes’ VELTIS technology and Paras Biopharmaceuticals’ Diabrid NobleCleav technology will create a superior osteoporosis medicine,” adds Dr Ashesh Kumar, Director of Biologics and Licensing, Paras Biopharmaceuticals Finland Oy.
Already well-established in the fields of diabetes, haemophilia and neutropenia, the VELTIS platform provides once-weekly, once bi-weekly or once-monthly peptide or protein dosing. As a result, VELTIS offers the potential for enhanced patient adherence and improved therapeutic impact.
“This is further market validation of the Novozymes Biopharma’s VELTIS technology”, says Svend Licht, Director, Novozymes Biopharma. “The versatile capabilities of our solution are being continually demonstrated by our customers. We are happy to enable the development of this biobetter, in addition to running numerous collaborations in life cycle management and new drug candidates.”
The agreement is not expected to impact Novozymes’ financial expectations for 2015.
EP News Bureau – Mumbai